Dry Age-Related Macular Degeneration Pipeline

DelveInsight’s, “Dry Age-Related Macular Degeneration Pipeline Insight, 2026” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Dry Age-Related Macular Degeneration pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

• Global coverage

Dry Age-Related Macular Degeneration Understanding

Dry Age-Related Macular Degeneration Overview

Dry Age-Related Macular Degeneration (Dry AMD) is a progressive chronic retinal disorder and the most common form of age-related macular degeneration, accounting for nearly 85%-90% of AMD cases. The disease primarily affects the macula, the central region of the retina responsible for sharp central vision required for reading, driving, and recognizing faces. Dry AMD is characterized by the accumulation of drusen (yellow lipid-rich deposits) beneath the retinal pigment epithelium, along with gradual degeneration of retinal pigment epithelial cells and photoreceptors, leading to progressive central vision loss. The condition typically progresses slowly through early, intermediate, and advanced stages, with geographic atrophy representing the late-stage form associated with irreversible retinal cell loss.

The signs and symptoms of dry AMD usually develop gradually and primarily affect central vision. Early symptoms may include blurred or distorted vision, difficulty reading or recognizing faces, reduced contrast sensitivity, and the need for brighter light during close-up activities. As the disease progresses, patients may experience dark or empty spots in the center of vision (central scotomas), impaired color perception, and increasing difficulty performing daily activities such as driving or reading.

The pathophysiology of Dry AMD involves progressive degeneration of the retinal pigment epithelium (RPE), photoreceptors, and underlying choriocapillaris within the macula. Aging, oxidative stress, mitochondrial dysfunction, chronic inflammation, and genetic susceptibility contribute to the accumulation of lipid-rich extracellular deposits known as drusen between the RPE and Bruch’s membrane. These deposits trigger complement system activation, inflammatory responses, and impaired nutrient and waste exchange, leading to RPE dysfunction and photoreceptor damage. Over time, continued cellular degeneration results in geographic atrophy, characterized by irreversible loss of retinal cells and progressive central vision impairment.

Diagnosis of dry AMD primarily relies on comprehensive ocular imaging and functional vision assessments. Clinical evaluation includes fundus examination to identify drusen, retinal pigment epithelium (RPE) abnormalities, and geographic atrophy. Advanced imaging modalities such as fundus autofluorescence (FAF) and spectral-domain optical coherence tomography (SD-OCT) are essential for detecting retinal thinning, photoreceptor loss, and disease progression. These imaging techniques, along with visual function testing, help classify disease severity, monitor progression, and improve early detection of retinal damage.

Management mainly focuses on slowing disease progression and preserving remaining retinal function. The AREDS and AREDS2 nutritional formulations containing antioxidant vitamins, zinc, lutein, and zeaxanthin have been shown to reduce the risk of progression to advanced AMD, particularly neovascular AMD. Emerging therapeutic strategies are targeting complement pathway dysregulation, oxidative stress, inflammation, amyloid deposition, autophagy, and retinal cell degeneration. In addition, stem cell-based therapies and retinal pigment epithelial cell replacement approaches are being investigated as potential regenerative treatments for advanced geographic atrophy.

"Dry Age-Related Macular Degeneration Pipeline Insight, 2026" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Dry Age-Related Macular Degeneration pipeline landscape is provided which includes the disease overview and Dry Age-Related Macular Degeneration treatment guidelines. The assessment part of the report embraces, in depth Dry Age-Related Macular Degeneration commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Dry Age-Related Macular Degeneration collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Discover the latest Dry Age-Related Macular Degeneration pipeline insights, emerging therapies, and clinical advancements shaping the future of treatment in 2026.

Dry Age-Related Macular Degeneration Pipeline Report Highlights

The Dry Age-Related Macular Degeneration companies and academics are working to assess challenges and seek opportunities that could influence Dry Age-Related Macular Degeneration R&D. The therapies under development are focused on novel approaches to treat/improve Dry Age-Related Macular Degeneration.

Dry Age-Related Macular Degeneration Emerging Drugs Analysis

This segment of the Dry Age-Related Macular Degeneration report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Dry Age-Related Macular Degeneration Emerging Drugs

Vonaprument: Annexon, Inc.

Vonaprument is an antigen-binding fragment (Fab) antibody designed as a first-in-kind therapeutic to selectively inhibit C1q, the initiating molecule of the classical complement pathway and a key driver of neurodegeneration. In advanced dry age-related macular degeneration (AMD) or geographic atrophy (GA), C1q binds to photoreceptor synapses, causing aberrant activation of the classical pathway with synapse loss, inflammation and neuronal damage that results in vision loss. Intravitreal administration of vonaprument fully stopped C1q and classical pathway activation. In animal models, the murine analog of vonaprument protected against loss of photoreceptor synapses and cells to preserve function. Currently, the drug is being evaluated in the Phase III stage of its development for the treatment of Dry Age-Related Macular Degeneration.

EG-301: Evergreen Therapeutics, Inc.

EG-301 is an investigational oral small-molecule drug developed by Evergreen Therapeutics designed to treat dry age-related macular degeneration (dry AMD), specifically in patients at high risk of progressing to geographic atrophy (GA). Currently, the drug is being evaluated in the Phase II stage of its development for the treatment of Dry Age-Related Macular Degeneration.

BS01: Bionic Sight LLC

BS01, an optogenetic gene therapy designed to restore sight in patients with retinal degenerative diseases like Retinitis Pigmentosa (RP) and Geographic Atrophy (GA). By delivering optogenetic proteins (ChronosFP) to the optic nerve, the therapy enables cells to convert light into neural signals. This aims to restore the flow of information from the retina to the brain, allowing patients to detect light, motion, and shapes. Currently, the drug is being evaluated in the Phase I/II stage of its development for the treatment of Dry Age-Related Macular Degeneration.

PST-611: PulseSight Therapeutics

PST-611 is a first-in-class, non-viral gene therapy developed by PulseSight Therapeutics to treat geographic atrophy (GA) secondary to dry age-related macular degeneration (AMD). By encoding human transferrin, it restores iron balance in the retina, reducing iron-induced toxicity, oxidative stress, and inflammation. It is a DNA plasmid-based therapy delivered to the ciliary muscle via electro-transfection, encouraging these cells to produce transferrin, which regulates iron and protects photoreceptors and retinal pigment epithelium (RPE) cells. Currently, the drug is being evaluated in the Phase I stage of its development for the treatment of Dry Age-Related Macular Degeneration.

Further product details are provided in the report……..

Dry Age-Related Macular Degeneration Drug Therapeutic Assessment

This segment of the report provides insights about the different Dry Age-Related Macular Degeneration drugs segregated based on following parameters that define the scope of the report, such as:

Major Dry Age-Related Macular Degeneration Players in Dry Age-Related Macular Degeneration

There are approx. 70+ key companies which are developing the therapies for Dry Age-Related Macular Degeneration. The companies which have their Dry Age-Related Macular Degeneration drug candidates in the most advanced stage, i.e. Phase III include, Annexon, Inc.

Dry Age-Related Macular Degeneration Clinical Trial Phases

DelveInsight’s report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

Dry Age-Related Macular Degeneration Drug Route of Administration

Dry Age-Related Macular Degeneration pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Oral
• Intravenous
• Subcutaneous
• Parenteral
• Topical

Dry Age-Related Macular Degeneration Product Molecule Type

Products have been categorized under various Molecule types such as

• Recombinant fusion proteins
• Small molecule
• Monoclonal antibody
• Peptide
• Polymer
• Gene therapy

Dry Age-Related Macular Degeneration Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Dry Age-Related Macular Degeneration Clinical Trial Activities

The Dry Age-Related Macular Degeneration pipeline report provides insights into different Dry Age-Related Macular Degeneration clinical trials within phase II, I, preclinical and discovery stage. It also analyses Dry Age-Related Macular Degeneration therapeutic drugs key players involved in developing key drugs.

Dry Age-Related Macular Degeneration Pipeline Development Activities

The Dry Age-Related Macular Degeneration clinical Trial analysis report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Dry Age-Related Macular Degeneration drugs.

Dry Age-Related Macular Degeneration Pipeline Report Insights

• Dry Age-Related Macular Degeneration Pipeline Analysis
• Dry Age-Related Macular Degeneration Therapeutic Assessment
• Dry Age-Related Macular Degeneration Unmet Needs
• Impact of Dry Age-Related Macular Degeneration Drugs

Dry Age-Related Macular Degeneration Report Assessment

• Dry Age-Related Macular Degeneration Pipeline Product Profiles
• Dry Age-Related Macular Degeneration Therapeutic Assessment
• Dry Age-Related Macular Degeneration Pipeline Assessment
• Dry Age-Related Macular Degeneration Inactive drugs assessment
• Dry Age-Related Macular Degeneration Market Unmet Needs

Discover actionable insights into the Dry Age-Related Macular Degeneration market trends, epidemiology trends, and forecast through 2036 to stay ahead in emerging therapies.

Key Questions Answered In The Dry Age-Related Macular Degeneration Pipeline Report:

• Current Treatment Scenario and Emerging Therapies:
• How many companies are developing Dry Age-Related Macular Degeneration drugs?
• How many Dry Age-Related Macular Degeneration drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Dry Age-Related Macular Degeneration?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Dry Age-Related Macular Degeneration therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Dry Age-Related Macular Degeneration and their status?
• What are the key designations that have been granted to the emerging drugs?

Dry Age-Related Macular Degeneration Key Players

• Annexon, Inc.
• Evergreen Therapeutics, Inc.
• PulseSight Therapeutics
• Bionic Sight LLC
• Luxa Biotechnology, LLC
• Ocugen
• Smilebiotek Zhuhai Limited
• Stealth BioTherapeutics Inc.
• Belite Bio
• Novartis Pharmaceuticals
• ONL Therapeutics
• Galimedix Therapeutics
• InflammX
• Aviceda Therapeutics
• Cognition Therapeutics
• SeaBeLife
• InMed Pharmaceuticals
• Avirmax Biopharma
• Character Biosciences
• Beacon Therapeutics

Dry Age-Related Macular Degeneration Key Products

• Vonaprument
• EG-301
• PST-611
• BS-01
• RPESC-RPE-4W
• OCU410
• QA102
• Elamipretide
• Tinlarebant
• Iptacopan
• Xelafaslatide
• GAL-101
• Tonabersat
• AVD-104
• Zervimesine
• SBL03
• INM089
• ABI201
• CTX203
• BTX-001

Explore comprehensive insights into Dry Age-Related Macular Degeneration epidemiology trends, patient population forecasts, and growth opportunities through 2034 for strategic decision-making.